Prescribers checklist for monitoring ongoing therapy in paediatric patients with:

Ritalin 10 or Artige or Ritalin LA

This checklist is designed to support you in the monitoring of ongoing therapy with Ritalin 10 or Artige or Ritalin LA in a child aged 6 years and above or an adolescent, with attention-deficit/hyperactivity disorder (ADHD).

As outlined in the Product Information in more detail, specific concurrent conditions may exclude the use of methylphenidate (MPH) or may warrant particular attention, including cardiovascular, cerebrovascular and neuropsychiatric disorders or symptoms. Importantly:

- Blood pressure and pulse should be recorded at each adjustment of dose and then at least every 6 months.
- Height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart.
- Development of de novo or worsening of preexisting psychiatric disorders should be monitored at every adjustment of dose and then at least every 6 months and at every visit.
- Children or adolescents who are being considered for treatment with stimulant medicine should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease.

DEPENDENCE: Ritalin and Artige should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow up.

It is recommended that this checklist be used in conjunction with the full Product Information for the individual product that is being prescribed.

Please use this checklist prior to your consultation. The completed checklist can be documented within the patient records.

As you work through the checklist, it may also be useful for you to discuss the Consumer Medicine Information (CMI) of the individual product that is being prescribed with your patient and their parent(s) or quardian(s).



Monitoring ongoing treatment with methylphenidate (MPH)

Reason for assessment:				
Patient name:				
Date of assessment:	Date of birth:	Age:	_ Gender:	
Carefully review the following sy at least every 6 months:	stems as indicated below <u>at each ac</u>	ljustment of dose and at f	ollow-up visits	
General medical findings			Evaluated	
Blood pressure and pulse (see se	eparate follow-up chart)			
Document height, body weight a	nd appetite (see separate follow-up o	chart)		
	Consider discontinuat	ion of MPH if growth is belo	w expectations	
Document any indication of abus	se, misuse or diversion of MPH			
Pregnancy				
Note any other relevant general r	medical findings			
	-	Evalu	ate benefit/risk	
New cardiovascular findings			Evaluated	
Blood pressure and pulse should	be recorded		Evaluatea	
Palpitations				
Exertional chest pain				
Unexplained syncope				
Dyspnoea				
Other symptoms suggestive of co				
	Refe	er for prompt specialist card		
New neurological findings			Evaluated	
Severe headache, numbness, we language or memory	akness or paralysis, impairment of co	ordination, vision, speech,		
Seizure frequency increase or ne	w-onset seizures			
		MPH should b	e discontinued	
New psychiatric findings or wors		odana ahaasidal baanaa ahaanad	Evaluated	
Psychotic or manic symptoms	ening of pre-existing psychiatric disor	ders snould be monitored		
r syoned of marile symptoms		Consider disconti	inuation of MPH	
Suicidal ideation or behaviour		Consider disconti	ridation of will ri	
Suicidal ideation of behaviour	Consider tree	atment of underlying psych	iatric condition	
	Consider trec	, . ,	ate benefit/risk	
		Consider disconti	inuation of MPH	
Aggressive and hostile behaviou	r			
	Consi	ider the need for adjustme	nt of treatment	
Anxiety, agitation or tension				
Depressive symptoms				
Motor or verbal tics or worsening	thereof			

New vascular findings	Evaluated		
Peripheral vasculopathy, including Raynaud's phenomenon			
Consider the need for adjustme	nt of treatment		
Priapism, abnormally sustained or frequent and painful erections			
Seek immediate me	edical attention		
Treatment duration	Evaluated		
Patient is being treated continuously for >12 months			
Data on safety and efficacy of long-term use of MPH are not complete. Patients requiring long-term therapy should be carefully monitored and periodic complete blood counts, differential and platelet counts are advisable during prolonged therapy. In the event of haematological disorders appropriate medical intervention should be considered			
Improvement in symptoms after appropriate dosage adjustment over a 1-month period is observed, otherwise drug discontinuation is recommended			
Consider trial period off medication at least once yearly to determine if continued treatment is still necessary			
Record any additional information here:			



Following the evaluation above, please complete the separate chart for 'Ongoing monitoring during methylphenidate (MPH) treatment' provided to record and track changes from baseline and during treatment.

End of treatment

Careful supervision is required during drug withdrawal, since this may unmask

- Depression as well as
- Chronic over activity

Some patients may require long-term follow-up.

Ritalin® 10 & Ritalin® LA: PBS and Product Information

PBS Information: Ritalin 10®. Authority required.

Use in attention deficit hyperactivity disorder, in accordance with State/Territory law. Ritalin LA®. Authority required. Treatment of attention deficit hyperactivity disorder (ADHD) in a patient diagnosed between the ages of 6 and 18 years inclusive, who has demonstrated a response to immediate release methylphenidate hydrochloride with no emergence of serious adverse events, and who requires continuous coverage over 8 hours.

DRUG DEPENDENCE:

Ritalin should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow up.



For healthcare professionals only. Please review full Product Information before prescribing. Scan QR code for full Ritalin® and Ritalin® LA Product Information

Alternately, please contact Medical Information at 1 800 671 203 or visit: https://www.novartis.com.au/products/healthcare-professionals/products to access the full Product Information

Artige®: PBS and Product Information

PBS Information: Artige®. Authority required. Use in attention deficit hyperactivity disorder, in accordance with State/Territory law.

DRUG DEPENDENCE:

Artige should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow up.



For healthcare professionals only. Please review full Product Information before prescribing. Scan QR code for full Artige Product Information

Alternately, please contact Medical Information at 1 800 671 203 or visit: https://www.novartis.com.au/products/healthcare-professionals/products to access the full Product Information

For the most up-to-date Product Information go to https://www.novartis.com.au/products/healthcare-professionals/products

®Registered trademark. @2025 Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Materloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. For medical enquiries please cortact 1800 671 203 or medinfo.phauno@novartis.com.

